根据药物学资料和缺乏老年急性髓细胞白血病(AML)可接受的标准疗法,作者采用了一种方案,研究29例平均年龄73岁(62～82岁)老年患者,其中10例由骨髓增生异常综合征(MDS)发展来而有继发性白血病。原始细胞数>50×10~9/L患者先用羟基脲降低原始细胞至<30×10~9/L。用阿糖胞苷连续静脉输注20mg/m~2/d,共21天,给阿糖胞苷前24 Based on pharmacological data and standard therapy that is lacking for acute myeloid leukemia (AML) in the elderly, the authors used a protocol to study 29 elderly patients, mean age 73 years (62-82 years), 10 of whom were diagnosed as having myelodysplastic Syndrome (MDS) to the development of secondary leukemia. The initial number of cells> 50 × 10 ~ 9 / L patients with hydroxyurea to reduce primitive cells to <30 × 10 ~ 9 / L. With cytarabine continuous intravenous infusion of 20mg / m ~ 2 / d, a total of 21 days to cytarabine 24